Position in KRYS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$726,985
+$310,058 QoQ
Shares Held
1,956
+21.2% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#214
of 419 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 79%
Shared 0%
None 21%
Common Shares in KRYS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Vident Advisory, LLC holds $52,462,395 across 42 Biotechnology names. KRYS ranks #19 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
148,975 | $8,105,728 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
28,409 | $6,845,716 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,522 | $6,220,051 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
7,804 | $4,866,104 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
13,776 | $2,579,967 | |
| 6 | LGND |
Ligand Pharmaceuticals Inc
|
6,151 | $1,944,268 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
5,518 | $1,661,083 | |
| 8 | CYTK |
Cytokinetics Inc
|
15,898 | $1,354,349 |
All Filings in KRYS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $726,985 | 1,956 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $416,927 | 1,614 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $368,330 | 1,494 | Shares | Defined | 2026-02-18 | |
| 2025-09-30 | $250,319 | 1,418 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $272,445 | 1,982 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $502,496 | 2,787 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $390,396 | 2,492 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $468,726 | 2,575 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $360,852 | 1,965 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $251,948 | 1,416 | Shares | Defined | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||